Cargando…

Awake intracerebroventricular delivery and safety assessment of oligonucleotides in a large animal model

Oligonucleotide therapeutics offer great promise in the treatment of previously untreatable neurodegenerative disorders; however, there are some challenges to overcome in pre-clinical studies. (1) They carry a well-established dose-related acute neurotoxicity at the time of administration. (2) Repea...

Descripción completa

Detalles Bibliográficos
Autores principales: Benatti, Hector Ribeiro, Prestigiacomo, Rachel D., Taghian, Toloo, Miller, Rachael, King, Robert, Gounis, Matthew J., Celik, Ugur, Bertrand, Stephanie, Tuominen, Susan, Bierfeldt, Lindsey, Parsley, Elizabeth, Gallagher, Jillian, Hall, Erin F., McElroy, Abigail W., Sena-Esteves, Miguel, Khvorova, Anastasia, Aronin, Neil, Gray-Edwards, Heather L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618110/
https://www.ncbi.nlm.nih.gov/pubmed/37920238
http://dx.doi.org/10.1016/j.omtm.2023.101122
_version_ 1785129706556751872
author Benatti, Hector Ribeiro
Prestigiacomo, Rachel D.
Taghian, Toloo
Miller, Rachael
King, Robert
Gounis, Matthew J.
Celik, Ugur
Bertrand, Stephanie
Tuominen, Susan
Bierfeldt, Lindsey
Parsley, Elizabeth
Gallagher, Jillian
Hall, Erin F.
McElroy, Abigail W.
Sena-Esteves, Miguel
Khvorova, Anastasia
Aronin, Neil
Gray-Edwards, Heather L.
author_facet Benatti, Hector Ribeiro
Prestigiacomo, Rachel D.
Taghian, Toloo
Miller, Rachael
King, Robert
Gounis, Matthew J.
Celik, Ugur
Bertrand, Stephanie
Tuominen, Susan
Bierfeldt, Lindsey
Parsley, Elizabeth
Gallagher, Jillian
Hall, Erin F.
McElroy, Abigail W.
Sena-Esteves, Miguel
Khvorova, Anastasia
Aronin, Neil
Gray-Edwards, Heather L.
author_sort Benatti, Hector Ribeiro
collection PubMed
description Oligonucleotide therapeutics offer great promise in the treatment of previously untreatable neurodegenerative disorders; however, there are some challenges to overcome in pre-clinical studies. (1) They carry a well-established dose-related acute neurotoxicity at the time of administration. (2) Repeated administration into the cerebrospinal fluid may be required for long-term therapeutic effect. Modifying oligonucleotide formulation has been postulated to prevent acute toxicity, but a sensitive and quantitative way to track seizure activity in pre-clinical studies is lacking. The use of intracerebroventricular (i.c.v.) catheters offers a solution for repeated dosing; however, fixation techniques in large animal models are not standardized and are not reliable. Here we describe a novel surgical technique in a sheep model for i.c.v. delivery of neurotherapeutics based on the fixation of the i.c.v. catheter with a 3D-printed anchorage system composed of plastic and ceramic parts, compatible with magnetic resonance imaging, computed tomography, and electroencephalography (EEG). Our technique allowed tracking electrical brain activity in awake animals via EEG and video recording during and for the 24-h period after administration of a novel oligonucleotide in sheep. Its anchoring efficiency was demonstrated for at least 2 months and will be tested for up to a year in ongoing studies.
format Online
Article
Text
id pubmed-10618110
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Society of Gene & Cell Therapy
record_format MEDLINE/PubMed
spelling pubmed-106181102023-11-02 Awake intracerebroventricular delivery and safety assessment of oligonucleotides in a large animal model Benatti, Hector Ribeiro Prestigiacomo, Rachel D. Taghian, Toloo Miller, Rachael King, Robert Gounis, Matthew J. Celik, Ugur Bertrand, Stephanie Tuominen, Susan Bierfeldt, Lindsey Parsley, Elizabeth Gallagher, Jillian Hall, Erin F. McElroy, Abigail W. Sena-Esteves, Miguel Khvorova, Anastasia Aronin, Neil Gray-Edwards, Heather L. Mol Ther Methods Clin Dev Original Article Oligonucleotide therapeutics offer great promise in the treatment of previously untreatable neurodegenerative disorders; however, there are some challenges to overcome in pre-clinical studies. (1) They carry a well-established dose-related acute neurotoxicity at the time of administration. (2) Repeated administration into the cerebrospinal fluid may be required for long-term therapeutic effect. Modifying oligonucleotide formulation has been postulated to prevent acute toxicity, but a sensitive and quantitative way to track seizure activity in pre-clinical studies is lacking. The use of intracerebroventricular (i.c.v.) catheters offers a solution for repeated dosing; however, fixation techniques in large animal models are not standardized and are not reliable. Here we describe a novel surgical technique in a sheep model for i.c.v. delivery of neurotherapeutics based on the fixation of the i.c.v. catheter with a 3D-printed anchorage system composed of plastic and ceramic parts, compatible with magnetic resonance imaging, computed tomography, and electroencephalography (EEG). Our technique allowed tracking electrical brain activity in awake animals via EEG and video recording during and for the 24-h period after administration of a novel oligonucleotide in sheep. Its anchoring efficiency was demonstrated for at least 2 months and will be tested for up to a year in ongoing studies. American Society of Gene & Cell Therapy 2023-09-26 /pmc/articles/PMC10618110/ /pubmed/37920238 http://dx.doi.org/10.1016/j.omtm.2023.101122 Text en © 2023 The Authors. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Benatti, Hector Ribeiro
Prestigiacomo, Rachel D.
Taghian, Toloo
Miller, Rachael
King, Robert
Gounis, Matthew J.
Celik, Ugur
Bertrand, Stephanie
Tuominen, Susan
Bierfeldt, Lindsey
Parsley, Elizabeth
Gallagher, Jillian
Hall, Erin F.
McElroy, Abigail W.
Sena-Esteves, Miguel
Khvorova, Anastasia
Aronin, Neil
Gray-Edwards, Heather L.
Awake intracerebroventricular delivery and safety assessment of oligonucleotides in a large animal model
title Awake intracerebroventricular delivery and safety assessment of oligonucleotides in a large animal model
title_full Awake intracerebroventricular delivery and safety assessment of oligonucleotides in a large animal model
title_fullStr Awake intracerebroventricular delivery and safety assessment of oligonucleotides in a large animal model
title_full_unstemmed Awake intracerebroventricular delivery and safety assessment of oligonucleotides in a large animal model
title_short Awake intracerebroventricular delivery and safety assessment of oligonucleotides in a large animal model
title_sort awake intracerebroventricular delivery and safety assessment of oligonucleotides in a large animal model
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618110/
https://www.ncbi.nlm.nih.gov/pubmed/37920238
http://dx.doi.org/10.1016/j.omtm.2023.101122
work_keys_str_mv AT benattihectorribeiro awakeintracerebroventriculardeliveryandsafetyassessmentofoligonucleotidesinalargeanimalmodel
AT prestigiacomoracheld awakeintracerebroventriculardeliveryandsafetyassessmentofoligonucleotidesinalargeanimalmodel
AT taghiantoloo awakeintracerebroventriculardeliveryandsafetyassessmentofoligonucleotidesinalargeanimalmodel
AT millerrachael awakeintracerebroventriculardeliveryandsafetyassessmentofoligonucleotidesinalargeanimalmodel
AT kingrobert awakeintracerebroventriculardeliveryandsafetyassessmentofoligonucleotidesinalargeanimalmodel
AT gounismatthewj awakeintracerebroventriculardeliveryandsafetyassessmentofoligonucleotidesinalargeanimalmodel
AT celikugur awakeintracerebroventriculardeliveryandsafetyassessmentofoligonucleotidesinalargeanimalmodel
AT bertrandstephanie awakeintracerebroventriculardeliveryandsafetyassessmentofoligonucleotidesinalargeanimalmodel
AT tuominensusan awakeintracerebroventriculardeliveryandsafetyassessmentofoligonucleotidesinalargeanimalmodel
AT bierfeldtlindsey awakeintracerebroventriculardeliveryandsafetyassessmentofoligonucleotidesinalargeanimalmodel
AT parsleyelizabeth awakeintracerebroventriculardeliveryandsafetyassessmentofoligonucleotidesinalargeanimalmodel
AT gallagherjillian awakeintracerebroventriculardeliveryandsafetyassessmentofoligonucleotidesinalargeanimalmodel
AT hallerinf awakeintracerebroventriculardeliveryandsafetyassessmentofoligonucleotidesinalargeanimalmodel
AT mcelroyabigailw awakeintracerebroventriculardeliveryandsafetyassessmentofoligonucleotidesinalargeanimalmodel
AT senaestevesmiguel awakeintracerebroventriculardeliveryandsafetyassessmentofoligonucleotidesinalargeanimalmodel
AT khvorovaanastasia awakeintracerebroventriculardeliveryandsafetyassessmentofoligonucleotidesinalargeanimalmodel
AT aroninneil awakeintracerebroventriculardeliveryandsafetyassessmentofoligonucleotidesinalargeanimalmodel
AT grayedwardsheatherl awakeintracerebroventriculardeliveryandsafetyassessmentofoligonucleotidesinalargeanimalmodel